文献速递技术与安全PETCTMR

淋巴瘤和多发性骨髓瘤PET/CT影像概述及近期进展

Overview and recent advances in PET/CT imaging in lymphoma and multiple myeloma.
PubMed 文献 · Eur J Radiol · 2021-05-27

本文综述[18F]FDG PET/CT在血液系统恶性肿瘤中的应用,重点涉及成人及儿童霍奇金淋巴瘤、弥漫大B细胞淋巴瘤和多发性骨髓瘤各阶段管理;视觉Deauville 5点评分和Lugano分类建议已标准化PET判读;[18F]FDG-PET常规推荐用于多发性骨髓瘤初始评估和疗效评估,但MRI仍是评估骨髓受累的金标准。

要点

  • 视觉Deauville 5点评分和Lugano分类建议已标准化淋巴瘤PET判读。
  • [18F]FDG PET/CT对所有FDG亲和性淋巴增殖性组织学类型的准确分期及早期和晚期疗效评估均必不可少。
  • [18F]FDG-PET常规推荐用于多发性骨髓瘤初始评估和疗效评估,MRI仍是骨髓受累评估金标准。

核心结论

  • [18F]FDG PET/CT对所有FDG亲和性淋巴增殖性组织学类型的准确分期及早期和晚期疗效评估必不可少,视觉Deauville 5点评分和Lugano分类建议已标准化PET判读;[18F]FDG-PET常规推荐用于多发性骨髓瘤初始评估和疗效评估,在风险分层和预后判断中有重要贡献,但MRI仍是骨髓受累评估的金标准。

研究设计与样本

  • 综述,检索范围与纳入文献原文未报告。

诊断标准与关键数值

  • 视觉Deauville 5点评分和Lugano分类建议已用于标准化PET判读并改善淋巴瘤患者管理。
  • [18F]FDG PET/CT对所有FDG亲和性淋巴增殖性组织学类型的准确分期及早期和晚期疗效评估必不可少。
  • [18F]FDG-PET常规推荐用于多发性骨髓瘤初始评估和疗效评估,在风险分层和预后判断中有重要贡献。
  • MRI仍是评估多发性骨髓瘤骨髓受累的金标准。

临床应用与阅片要点

  • 对FDG亲和性淋巴瘤,[18F]FDG PET/CT用于准确分期及早期和晚期疗效评估。
  • 淋巴瘤PET判读采用视觉Deauville 5点评分和Lugano分类建议。
  • 多发性骨髓瘤初始评估和疗效评估常规推荐[18F]FDG-PET,但其骨髓受累评估仍以MRI为金标准。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Imaging in hematological diseases has evolved extensively over the past several decades. Positron emission tomography/computed tomography (PET/CT) with of 2-[18 F]-fluoro-2-deoxy-d-glucose ([18 F] FDG) is currently essential for accurate staging and for early and late therapy response assessment for all FDG-avid lymphoproliferative histologies. The widely adopted visual Deauville 5-point scale and Lugano Classification recommendations have recently standardized PET scans interpretation and improved lymphoma patient management. In addition [18 F] FDG-PET is routinely recommended for initial evaluation and treatment response assessment of Multiple Myeloma (MM) with significant contribution in risk-stratification and prognostication, although magnetic resonance imaging remains the Gold Standard for the assessment of bone marrow involvement. In this review, an overview of the role of [18 F] FDG-PET, in hematological malignancies is provided, particularly focusing on Hodgkin lymphoma (HL) and Diffuse Large B Cell Lymphoma (DLBCL), both in adult and pediatric populations, and MM, at each point of patient management. Potential alternative molecular imaging applications in this field, such as non-[18 F] FDG-tracers, whole body magnetic resonance imaging (WB-MRI), hybrid PET/MRI and emerging radiomics research are briefly presented.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Zanoni L, Mattana F, Calabrò D, et al. Overview and recent advances in PET/CT imaging in lymphoma and multiple myeloma. Eur J Radiol. 2021. PMID: 34148014. doi:10.1016/j.ejrad.2021.109793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。